ArticleFrontiers in oncology2023

Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.

Long-Wang Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.